Evaluation of losmapimod in patients with chronic obstructive pulmonary disease (COPD) with systemic inflammation stratified using fibrinogen (‘EVOLUTION’): Rationale and protocol
Introduction: p38 mitogen-activated protein kinases (MAPK) are key signalling molecules in cellular responses to external stresses, regulate pro-inflammatory cytokine expression and are implicated in the inflammatory pathogenesis of Chronic Obstructive Pulmonary Disease (COPD) and atherosclerosis. T...
Main Authors: | M. Fisk, D. Mohan, J. Cheriyan, L. Yang, J. Fuld, C.M. McEniery, R. Tal-Singer, M.I. Polkey, I.B. Wilkinson |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2013-11-01
|
Series: | Artery Research |
Subjects: | |
Online Access: | https://www.atlantis-press.com/article/125925225/view |
Similar Items
-
Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
by: Yukio Nishimura
Published: (2018-02-01) -
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
by: Yiu To Yeung, et al.
Published: (2018-02-01) -
Losmapimod Protected Epileptic Rats From Hippocampal Neuron Damage Through Inhibition of the MAPK Pathway
by: Min Li, et al.
Published: (2019-06-01) -
The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
by: Marie Fisk, et al.
Published: (2018-01-01) -
Experimental Agents for the Treatment of Atherosclerosis: New Directions
by: Voutyritsa E, et al.
Published: (2021-02-01)